

1 **Multi-omics Analysis of Umbilical Cord Hematopoietic Stem Cells from a**
2 **Multi-ethnic Cohort of Hawaii Reveals the Intergenerational Effect of**
3 **Maternal Pre-Pregnancy Obesity and Risk Prediction for Cancers**

4
5 Yuheng Du¹, Paula A. Benny², Yuchen Shao³, Ryan J. Schlueter², Alexandra Gurary², Annette
6 Lum-Jones⁴, Cameron B Lassiter⁴, Fadhl M. AlAkwa⁵, Maarit Tiirikainen⁴, Dena Towner², W.
7 Steven Ward², Lana X Garmire^{1*}

8
9 1. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann
10 Arbor, MI

11 2. Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, HI

12 3. Department of Electrical Engineering and Computer Science, University of Michigan, Ann
13 Arbor, MI

14 4. University of Hawaii Cancer Center, Population Sciences of the Pacific Program-
15 Epidemiology, Honolulu, HI

16 5. Department of Neurology, University of Michigan, Ann Arbor, MI

17 *. Corresponding author email: lgarmire@med.umich.edu

18

- 19 **Keywords: obesity, Native Hawaiian, Hematopoietic stem cells, Multi-omics, cord blood,**
20 **methylation, pregnancy**
- 21 **Abbreviation:**
- 22 **AA:** Amino Acid
- 23 **BH:** Benjamini-Hochberg
- 24 **BMI:** Body mass index
- 25 **C:** Acylcarnitines
- 26 **DE:** Differential expression
- 27 **DIABLO:** Data Integration Analysis for Biomarker discovery using Latent cOmponents
- 28 **DM:** Differential methylation
- 29 **DMR:** Differentially methylated regions
- 30 **DOHaD:** Developmental Origins of Health and Disease
- 31 **EWAS:** Epigenome-wide association studies
- 32 **FC:** Fold Change
- 33 **FDR:** False positive results
- 34 **KEGG:** Kyoto Encyclopedia of Genes and Genomes
- 35 **LOG:** Logistic regression
- 36 **MDS:** Multi-dimensional Scaling
- 37 **NHPI:** Native Hawaiian and Pacific Islander
- 38 **PANDA:** Preferential Attachment-based common Neighbor Distribution derived Associations
- 39 **PC aa:** Diacyl phosphatidylcholines
- 40 **PC ae:** Acyl-alkylphosphatidylcholines
- 41 **PCC:** Pearson correlation coefficients

- 42 **PPI**: Protein-Protein Interaction
- 43 **RF**: Random Forest
- 44 **SOV**: Source of variance
- 45 **SVD**: Singular value decomposition
- 46 **SVA**: Surrogate variable analysis
- 47 **TSS**: Transcription start site
- 48 **TCGA**: The Cancer Genome Atlas
- 49 **uHSCs**: Umbilical cord blood hematopoietic stem cells
- 50 **UMAP**: Uniform Manifold Approximation and Projection
- 51 **VSN**: Variance Stabilization Normalization
- 52 **WGCNA**: Weighted Gene Co-expression Network Analysis
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64

65 **Abstract**

66 **Background:** Maternal obesity is a health concern that may predispose newborns to a high risk
67 of medical problems later in life. To understand the intergenerational effect of maternal obesity,
68 we hypothesized that the maternal obesity effect is mediated by epigenetic changes in the
69 CD34+/CD38-/Lin- hematopoietic stem cells (uHSCs) in the offspring. Towards this, we
70 conducted a DNA methylation centric multi-omics study. We measured the DNA methylation
71 and gene expression in the CD34+/CD38-/Lin- uHSCs and metabolomics of the cord blood, all
72 from a multi-ethnic cohort (n=72) from Kapiolani Medical Center for Women and Children in
73 Honolulu, Hawaii (collected between 2016 and 2018).

74 **Results:** Differential methylation (DM) analysis unveiled a global hypermethylation pattern in
75 the maternal pre-pregnancy obese group (BH adjusted $p < 0.05$), after adjusting for major clinical
76 confounders. KEGG pathway enrichment, WGCNA, and PPI analyses revealed hypermethylated
77 CpG sites were involved in critical biological processes, including cell cycle, protein synthesis,
78 immune signaling, and lipid metabolism. . Utilizing Shannon entropy on uHSCs methylation, we
79 discerned notably higher quiescence of uHSCs impacted by maternal obesity. Additionally, the
80 integration of multi-omics data-including methylation, gene expression, and metabolomics-
81 provided further evidence of dysfunctions in adipogenesis, erythropoietin production, cell
82 differentiation, and DNA repair, aligning with the findings at the epigenetic level. Furthermore,
83 we trained a random forest classifier using the CpG sites in the genes of the top pathways
84 associated with maternal obesity, and applied it to predict cancer vs. adjacent normal labels from
85 samples in 14 Cancer Genome Atlas (TCGA) cancer types. Five of 14 cancers showed balanced
86 accuracy of 0.6 or higher: LUSC (0.87), PAAD (0.83), KIRC (0.71), KIRP (0.63) and BRCA
87 (0.60).

88 **Conclusions:** This study revealed the significant correlation between pre-pregnancy maternal
89 obesity and multi-omics level molecular changes in the uHSCs of offspring, particularly in DNA
90 methylation. Moreover, these maternal obesity epigenetic markers in uHSCs may predispose
91 offspring to higher risks in certain cancers.

92

93 **Introduction**

94 Maternal obesity has emerged as a primary health concern during pregnancy, with its prevalence
95 alarmingly increasing. According to a study by the Centers for Disease Control and Prevention,
96 the percentage of women experiencing pre-pregnancy obesity in the United States escalated from
97 26% to 29% between 2016 and 2019 ¹. Born to mothers with obesity, higher birth weight is
98 associated with a higher incidence of childhood cancers such as leukemia and neuroblastoma ^{2,3},
99 as well as greater risks of prostate and testicular cancers in men ⁴⁻⁶ and breast cancer in women ⁷.
100 Moreover, maternal obesity may have a intergenerational effect and set the stage for increased
101 chronic disease susceptibility later in the adulthood of offspring ^{8,9}. The hypothesis of the utero
102 origin of diseases proposes that numerous chronic diseases have their origins in the fetal stage,
103 the earliest phase of human development ^{10,11}. Some researchers have speculated higher stem cell
104 burdens in newborn babies born from obese mothers ¹². Altered hormonal environment and
105 nutrient availability can induce critical changes in fetal stem cells ¹³, which may predispose these
106 cells to malignant transformation, aligning with the idea of the cancer stem cell hypothesis that
107 cancer cells have stem cell-like properties with an uncontrolled self-renewal program ¹⁴⁻¹⁶. In
108 particular, a study showed increases in cord blood CD34+CD38- stem cell and CD34+
109 progenitor cell concentrations with maternal obesity ¹⁷, suggesting that the higher proportions of
110 stem cells in cord blood may make the babies more susceptible to obesity and cancer risks.

111 However, so far little work provides direct molecular links as to how maternal obesity affects
112 cellular function and increases the disease risk in offspring.
113 To seek answers in this area, we conducted an epigenome-centered multi-omics study to directly
114 pinpoint the effect of maternal obesity in umbilical cord blood hematopoietic stem cells
115 (uHSCs). Epigenetics is chosen as the center of multi-omics integration, as it is both inheritable
116 and susceptible to modification by diseases. Thus, it may serve as a plausible mediator in the
117 transmission of the effects of maternal obesity to offspring. We incorporate gene expression for
118 cord blood stem cells and metabolomics data from the cord blood serum as the downstream
119 readout of epigenetics changes. By elucidating these molecular connections, we provide a
120 systematic understanding of how maternal obesity during pregnancy can influence the multiple
121 types of molecular profiles of newborns. Such knowledge may ultimately help develop early
122 therapeutic interventions at the molecular level to mitigate these intergenerational health risks
123 due to maternal obesity.

124

125

126 **Methods**

127

128 **Overview of the maternal pre-pregnancy cohort with baby cord blood**

129 In this study, baby cord blood samples from 72 pregnant women (34 obese; 38 non-obese) who
130 delivered at Kapiolani Medical Center for Women and Children in Honolulu, Hawaii (2015-
131 2018) were collected. The study was approved by the Western IRB (WIRB Protocol
132 #20151223). Patients meeting the inclusion criteria were identified from pre-admission medical
133 records with pre-pregnancy BMI \geq 30.0 (maternal obesity) or 18.5-25.0 (normal weight).

134 Pregnant women undergoing elected C-sections at ≥ 37 weeks gestation were included, to
135 minimize confounding events during the labor. Patient exclusion criteria included pregnant
136 women with preterm rupture of membranes, labor, multiple gestations, pregestational diabetes,
137 hypertensive disorders, cigarette smokers, infection of human immunodeficiency virus or
138 hepatitis B virus, and chronic drug use. Demographic and phenotypic information was recorded,
139 including maternal and paternal age, ethnicity, gestational weight gain, gestational age, parity,
140 and gravidity. For newborns, Apgar scores were documented at 1 minute and 5 minutes post-
141 delivery. The Apgar score serves as a comprehensive assessment of a newborn's health, with a
142 normal range considered to be between 7 to 10¹⁸.

143

144 **Sample preparation and methylation profiling**

145 The baby cord blood sample was collected in the operating room under sterile conditions at the
146 time of the C-section (Pall Medical Cord Blood Collection Kit containing 25ml citrate phosphate
147 dextrose). The umbilical cord was first cleansed with chlorhexidine swabs before cord blood
148 collection. The total volume of collected blood was measured and recorded before aliquoting to
149 conical tubes for centrifugation. The tubes were centrifuged at 200g for 10 min, and plasma was
150 collected. The plasma volume was replaced with 2% FBS/PBS. Negative selection reagents were
151 added to the blood and incubated for 20 min (Miltenyi Biotec, Auburn, CA). The cord blood was
152 diluted with an equal volume of 2% FBS/PBS. A 20ml aliquot of the diluted blood was layered
153 over a density gradient (15ml Lymphoprep) and centrifuged at 1200g for 20 min. The top layer
154 containing an enriched population of stem cells was collected, centrifuged at 300g for 8 min, and
155 then washed in 2% FBS/PBS. Red blood cells were lysed using ammonium chloride (9:1) with
156 incubation on ice for 10 min, washed twice, and then resuspended in 100 μ l of 2% FBS/PBS.

157 Cells were stained with Lineage FITC and CD34 APC for 45 min on ice, washed twice, and then
158 sorted using the BD FACS Aria III. Hematopoietic stem cells (CD34⁺/CD38⁻/Lin⁻) were collected
159 and stored at -80°C until DNA/RNA extraction.

160 DNA and RNA were extracted simultaneously using the AllPrep DNA/RNA extraction kit
161 (Qiagen). DNA purity and concentration were quantified in Nanodrop 2000 and Picogreen assay.
162 Bisulfite conversion of 500 ng DNA was performed using the EZ DNA Methylation kit (Zymo),
163 followed by sample processing for Infinium HumanMethylation450 bead chips (Illumina)
164 according to the manufacturer's instructions. Bead chips were analyzed at the Genomics Shared
165 Resource at the University of Hawaii Cancer Center.

166

167 **Bulk RNA sequencing**

168 A total of 50 RNA samples were prepared for bulk RNA Sequencing. RNA concentration and
169 RIN score were assayed using Nanodrop 2000 and Agilent Bioanalyzer. A total of 200 ng of
170 high-quality RNA (RIN_≥7) was subjected to library construction (polyA) and sequenced on
171 HS4000 (2x100) at the Yale Center for Genome Analysis, Connecticut to obtain at least 25M
172 paired reads per sample.

173

174 **Methylation data pre-processing**

175 The overall preprocessing workflow is shown in **Supplemental Figure 1**. R version 3.6.3 was
176 used for all analyses. As the first step of quality assessment, sex chromosome methylation
177 patterns were analyzed to check for potential sex mismatches between reported and inferred sex
178 using the getSex() function in minfi¹⁹. No samples with discrepancies between reported and
179 inferred sex were identified or flagged for exclusion **Supplemental Figure 2A**. Raw intensity

180 data (.idat) were extracted using the ‘ChAMP’ package (version 2.16.2) in R with *champ.load()*
181 function^{19–22}. For the filtration step, background controls were subtracted from the data, and raw
182 data that did not pass detection P-value of 0.05 were removed. CpG sites whose probes had
183 known underlying SNPs and association with XY chromosomes were removed from analysis due
184 to potential confounding. The quality controls included checking the raw density distribution,
185 multi-dimensional scaling (MDS) plot, and median intensity values of methylated and
186 unmethylated probes to identify potential outliers or poorly performing samples (**Supplemental**
187 **Figure 2B-D**). After BMIQ normalization using *champ.norm()* function²³, the batch effect
188 (including slide and array) due to non-biological technical variation caused by experiment
189 handling was removed using the ComBat function in the ChAMP package, confirmed by the
190 singular value decomposition (SVD) plot (**Supplemental Figure 2E**). A total of 1,992 cross-
191 hybridizing probes were removed using the probe list from ExperimentHub (query id ‘EH3129’)
192 as reported in Chen et al. 2013²⁴. For each CpG site, the methylation score was initially
193 calculated as the beta value, a fluorescence intensity ratio between 0 and 1. To reduce the
194 heteroskedasticity for downstream statistical analysis, the M-values were transformed from beta-
195 values using lumi (ver 3.1.4) in R^{25–28}. A total of 408,773 CpG sites remained for downstream
196 analysis after probe filtering, quality control, normalization, batch correction, and cross-
197 hybridizing probes removal.

198

199 **Source of variation analysis and confounding adjustment**

200 To eliminate potential confounding factors of pre-pregnant maternal obesity among the 13
201 clinical factors, we conducted a source of variation analysis with a collection of ANOVA tests to
202 identify the clinical factors that significantly contribute to the methylation level variation, as

203 done before ^{29,30}. The variables with F statistics greater than 1 (the error value) were determined
204 as confounders and subjected to confounding adjustment. These factors include the baby's sex,
205 net weight gain during the pregnancy, maternal age, maternal ethnicity, paternal ethnicity,
206 gravidity, and gestational age. To adjust for confounding effects, a multivariate regression model
207 is built using the 'limma' package to fit methylation M values of each CpG site, using the
208 confounding factors above. The remaining residuals on the M values were considered to be
209 confounding adjusted for the subsequent bioinformatics analysis of DNA methylation. To assess
210 the bias and inflation in the differential methylation findings, we used Bayesian method "bacon"
211 to calculate the genomic inflation (lambda) values before and after the confounder adjustment ³¹.
212 Additional surrogate variable analysis (sva) and randomly shuffled null lambda calculation were
213 performed to determine the need for inflation adjustment ³². The null model lambda was 0.96. No
214 surrogate variables were identified for correction in the adjusted model. Thus the observed
215 inflation reflects the true biological signal rather than systematic bias, and no further inflation
216 correction was performed on this confounder adjusted model.

217

218 **Bioinformatics analysis of differential methylation (DM)**

219 A moderated t-test from the 'limma' R package (version 3.42.2) ³³ was used for detecting DM
220 CpG sites between healthy controls and cases with M values. The p-values were adjusted for
221 multiple hypotheses testing using Benjamini-Hochberg FDR. CpG sites with FDR <0.05 were
222 considered statistically significant. To minimize the effect of the gestational age, CpG sites
223 located within the gestational-age-related differentially methylated regions (DMR) were
224 removed. A total of 130 DMRs related to gestational age were identified using linear regression
225 analysis performed with bumpHunter ³⁴ across eight public datasets including a total of 248

226 patients.: GSE31781 ³⁵, GSE36829 ³⁶, GSE59274 ^{35,37}, GSE44667 ³⁸, GSE74738 ³⁹, GSE49343
227 ⁴⁰, GSE69502 ⁴¹, and GSE98224 ^{42,43}. The complete list of DMRs was included in **Supplemental**
228 **Table 1**. Hypermethylation and hypomethylation states were defined by the values of log₂ Fold
229 Change (log₂FC) of M values in cases compared to controls: hypermethylation if bigger than 0,
230 and hypomethylation if less than 0. Corresponding genes and feature locations of these
231 differential CpG sites were annotated using IlluminaHumanMethylation450kanno.ilmn12.hg19
232 (ver 0.6.0) ⁴⁴ .

233

234 **KEGG pathway enrichment analysis**

235 ‘gometh’ function from R package “missMethyl” (version 1.26.1) ^{45–48} was used for KEGG
236 pathway enrichment ^{49–51} with DNA methylation data. DM sites were used for pathway
237 enrichment within five supergroups from KEGG pathways: Metabolism, Genetic Information
238 Processing, Environmental Information Processing, Cellular Processes, and Organismal Systems.
239 Pathways with adjusted p-values less than 0.05 were considered significant. Pathway scores for
240 protein pathways (KEGG: Transcription, Translation, Folding, sorting and degradation) and
241 immune pathways (KEGG: Immune system) were calculated with averaged beta values from the
242 promoter region CpG sites. To validate the enrichment of significant CpGs in specific pathways,
243 we used the hypergeometric test, which calculates the probability of observing k or more
244 significant CpGs in a pathway by chance, given the total CpGs on the Illumina array (N), the
245 total CpGs in the pathway (K), and the total significant CpGs identified in our study (n). The
246 formula is: $P(X \geq k) = 1 - \sum_{i=0}^{k-1} \frac{\binom{KN-K}{i} \binom{n-i}{N-i}}{\binom{n}{N}}$, where $\frac{a}{b}$ represents the binomial coefficient.

247

248 **Weighted co-expression network analysis**

249 Firstly, we adjusted all beta values with clinical confounders, then summarized the DM CpG
250 sites at the gene level by averaging the beta values in the promoter regions (those in the TSS200
251 and TSS1500 promoter regions). Next, we transformed adjusted beta values to adjusted M values
252 for the downstream adjacency matrix construction. We used adjusted M values for the weighted
253 gene co-expression network analysis (WGCNA) with R package ‘WGCNA’ (version 1.70-3)
254 ^{52,53}. The soft threshold for the weighted adjacency matrix with an adjusted $R^2 > 0.8$ was 7. The
255 topological overlap matrix was constructed for hierarchical clustering. Modules were identified
256 by the dynamic tree-cut algorithm. The networks were exported to Cytoscape with an edge
257 weight greater than 0.03 in each module. The genes with the highest betweenness and degree in
258 the WGCNA network were identified as the hub genes for different modules.

259

260 **Protein-protein interaction network analysis**

261 For the protein-protein interaction (PPI) network analysis, DM genes are used as the inputs and
262 were mapped on the STRING database (version 10) ⁵⁴. Significantly functionally associated
263 protein pairs were identified using PANDA (Preferential Attachment based common Neighbor
264 Distribution derived Associations) (version 0.9.9) ⁵⁵. KEGG pathways associated with these
265 protein pairs (in terms of genes) were found using PANDA. The bipartite network graph was
266 visualized using Cytoscape (version 3.8.1) ⁵⁶.

267

268 **Stemness score computation**

269 The stemness score was based on Shannon entropy and scaled plasticity, as proposed previously
270 ⁵⁷. Shannon entropy has been widely applied in developmental biology, particularly in stem cell
271 research ⁵⁸⁻⁶⁰. The formulas are shown below:

$$Entropy = \sum_{i=1}^N \frac{\frac{CpG_i}{N} \log\left(\frac{CpG_i}{\sum_{i=1}^N CpG_i}\right)}{\log(N)}$$

$$StemnessScore = \frac{Entropy - \min(Entropy)}{\max(Entropy) - \min(Entropy)}$$

272

273 N is the total number of CpG sites. CpG is represented by the beta value on each CpG probe.

274 The stemness score was calculated for all samples using all remaining 408,773 CpG sites after

275 the preprocessing. A Wilcoxon rank test was performed between the stemness scores of the

276 healthy and maternally obese groups.

277

278 **Bulk RNA-seq data processing**

279 The Illumina universal adapter regions of raw RNA-seq data were first trimmed using BBDNA

280 (version 38.91) ⁶¹. All raw sequences passed the quality control using fastqc (version 0.11.8) ⁶².

281 The trimmed .fastq files were aligned by STAR (version 2.7.0f) ⁶³ to the human Ensembl

282 genome (Homo_sapiens.GRCh38.dna.primary_assembly.fa) and Ensembl annotation

283 (Homo_sapiens.GRCh38.94.gtf). The gene expression counts were calculated using featureCount

284 ⁶⁴ from Subread (ver 1.6.4) ⁶⁵.

285

286 **Differential expression (DE) of RNA-Seq data**

287 The limma voom transformation was used on RNA-seq data to model the mean-variance

288 relationship of the log2 counts ⁶⁶, supporting the empirical Bayes analysis pipeline in limma

289 (**Supplemental Figure 3A**). Source of variance analysis was performed to find the clinical

290 confounders with ANOVA tests. The significant confounders included: Maternal_Age, baby sex,

291 hemoglobin, sample group, net weight gain, maternal ethnicity, gravidity and parity

292 **(Supplemental Figure 3B)**. The statistically significant DE genes between healthy controls and
293 maternally obese cases were found with confounder adjustment using the ‘DESeq2’ (version
294 1.26.0)⁶⁷ and ‘limma-voom’ function from ‘limma’ package³³. The p-values were adjusted for
295 multiple hypotheses testing using BH adjustment. No significant differential genes were found
296 with adjusted p-values less than 0.05.

297

298 **Correlation analysis between bulk RNA-seq and methylation data**

299 A subset of 47 patients have done both methylation and RNA-seq assays. Pearson correlation
300 coefficients (PCC) were calculated between gene expression and methylation beta values from
301 the promoter regions, among the same patients. As mostly a negative correlation between gene
302 expression and DNA methylation in the promoter region is expected, genes with a high negative
303 correlation (PCC<-0.2) were used for pathway enrichment using TOPPFUN⁶⁸⁻⁷⁰. Top genes of
304 interest were selected with the absolute value Fold Change>1.5 in gene expression and gene-
305 methyl correlation <-0.3 for hyper- and hypo-methylated CpG sites.

306

307 **Metabolomics analysis**

308 Metabolomics data were acquired from a previously published study involving 87 patients in the
309 same cohort from three batches (metabolomics workbench study ID ST001114)⁷¹. Targeted
310 metabolites were generated with LC-MS, and untargeted metabolites were generated with GC-
311 MS. After the removal of compounds missing in more than 10% of samples, a total of 185
312 metabolites remained, including 10 amino acids (AA), 40 acylcarnitines (C), 35 acyl/acyl
313 phosphatidylcholines (PC aa), 38 acyl/alkyl phosphatidylcholines (PC ae) and 62 untargeted
314 metabolites. The raw metabolite data were log-transformed, standardized, normalized using

315 variance stabilization normalization (VSN), and batch corrected with ComBat function in sva
316 package⁷². Differential metabolites were identified by limma, with clinical confounders
317 adjustment.

318

319 **Multi-omics integration on metabolomics, epigenomics, and transcriptomics**

320 A subset of 42 patients have the matched methylation, gene expression, and metabolomics data.
321 We applied multi-omics integration with Data Integration Analysis for Biomarker discovery
322 using Latent cOmponents (DIABLO) implemented in the mixOmics package⁷³. DIABLO finds
323 the correlated consensus latent variables among different omics in the supervised manner. Top
324 DIABLO features for each omic were selected based on the loading values. We integrated the
325 pathway-level methylation, gene, and metabolite interaction using pathview⁷⁴.

326

327 **Evaluation of maternal pre-pregnancy obesity biomarkers in cancer prediction**

328 We collected Infinium HumanMethylation450 data for a total of 14 cancer datasets (adjacent
329 normal samples > 10): BLCA, BRCA, COAD, ESCA, HNSC, KIRC, KIRP, LIHC, LUAD,
330 LUSC, PAAD, PRAD, THCA, UCEC from The Cancer Genome Atlas (TCGA data portal:
331 <https://portal.gdc.cancer.gov/>). In total, 6428 samples were obtained, consisting of 5715 tumor
332 samples and 713 adjacent normal tissues.

333 To build the obesity classification model with maternal obesity biomarkers, we selected 61
334 hypermethylated CpG sites from the promoter regions of the genes involved in the top five
335 significant pathways based on the missMethyl KEGG enrichment results. This includes cell
336 cycle, ribosome, nucleocytoplasmic transport, ribosome biogenesis in eukaryotes, and mTOR
337 signaling pathway. We split the 72 maternal obesity and control samples at a ratio of 80/20 with

338 5-fold cross-validation, then constructed a series of classification methods using the *liliko* R
339 package, where Random Forest (RF) was the winning model ^{75,76}. Next, we applied this RF
340 obesity model on 14 TCGA dataset to perform cancer/normal sample prediction. We report
341 accuracy, balanced accuracy, and F1 score for model performance as done before ⁷⁵.

342

343 **Results**

344

345 **Overview of study design and cohort characteristics**

346 This study aims to investigate the intergenerational effect of pre-pregnancy maternal obesity on
347 offspring. A total of 72 patients who elected to deliver full-term babies through C-sections were
348 recruited from Kapiolani Medical Center for Women and Children in Honolulu, Hawaii from
349 2016 to 2018. This cohort reflects the multi-ethnic population character of Hawaii, including
350 Asian (N=29), Caucasian (N=15), and Native Hawaiian and Pacific Islanders or NHPs (N=28).
351 Among them, 38 deliveries are in the healthy control group and 34 are cases with pre-pregnancy
352 maternal obesity. We excluded natural virginal births, to avoid its potential confounding effect
353 on multi-omics profiles. We also carried out stringent recruitment selection criteria, including
354 matching the mothers' ages as much as possible, as well as similar net gestational weight gain to
355 minimize its confounding effect over maternal pre-pregnancy maternal obesity. The overall
356 study design is shown in **Figure 1**. Briefly, upon collecting the blood samples, umbilical cord
357 blood hematopoietic stem cells (uHSCs) were enriched by FACS sorting with CD34+CD35-
358 LIN- markers (see **Methods**). We extracted DNA and RNA from these uHSCs for Illumina
359 450k array based DNA methylation and bulk RNA-Seq sequencing respectively. The plasma
360 from these cord blood samples was subject to untargeted metabolomics assays using GC-MS and

361 targeted metabolomics assays using LC–MS⁷¹. Given the rationale that DNA methylation could
362 be the mediator for exerting the intergenerational effect of maternal obesity^{77,78}, we carried out
363 multi-omics data integration analysis in the DNA methylation-centric manner.

364

365 The demographic details and clinical information of these patients are summarized in **Table 1**.
366 The distributions of the most representative variables are shown in **Figure 2**. Among categorical
367 demographic variables, the distribution of baby sex had no statistical difference between obese
368 and health groups, whereas the ethnicity distributions among mothers and fathers, parity and
369 gravidity are statistically different ($P < 0.05$) between the two groups (**Figure 2A-2E**). Besides
370 maternal pre-pregnancy BMI, other maternal parameters such as maternal age, gestational week,
371 net weight gain and hemoglobin are also not statistically significantly different between the two
372 groups per study design (**Figure 2F-2I, Table 1**). While mothers of Asian ethnicity are the
373 majority in the control group, NHPs account for the majority of the maternal-obese group,
374 revealing the health disparity issue known in the state of Hawaii⁷⁹. Moreover, the control group
375 has lower parities and gravidities, compared to the cases. Babies born to obese mothers show
376 significantly higher ($P < 0.05$) body weights compared to the control group, as expected⁸⁰. Other
377 parameters including the baby gender, head circumference, body length, and APGAR score at 5
378 min after birth are not statistically significantly different between case and control groups
379 (**Figure 2J-2M**).

380

381 **Global hypermethylation pattern revealed by CpG level methylation analysis**

382 Quality control of methylation data showed no significant sample outliers and no remaining
383 batch effect after ComBAT correction (**Supplemental Figure 2D**). For scientific rigor, it is

384 critical to adjust for confounding in DNA methylation association analysis⁸¹. Thus we
385 performed the source of variance (SOV) analysis on the beta values of the DNA methylation
386 with respect to physiological and phenotypic information, in order to assess potential
387 confounding factors systematically^{29,30,81}. As shown in **Figure 3A**, marginal F-statistics in the
388 SOV analysis show that the dominating contribution to DNA methylation variation is maternal
389 pre-pregnancy obesity status, confirming the quality of the study design which aimed to
390 minimize other confounders' effect. The other minor confounding factors include baby sex,
391 maternal age, maternal ethnicity, net weight gain during pregnancy, paternal ethnicity, gravidity,
392 and gestational age (F-statistics>1). After adjusting these factors by linear regression, all have
393 reduced F-statistics of less than 0.5 (**Figure 3B**) except maternal pre-pregnancy obesity,
394 confirming the success of confounding removal. The quantile-quantile (QQ) plot and genomic
395 inflation factor were used to assess the confounder adjusting model (**Supplemental Figure 4**). A
396 decrease in genomic inflation factor (lambda) was observed with adjustment of confounders.
397 Although the adjusted model had lambda of 1.28, no surrogate variables were identified for
398 correction in the adjusted model. Therefore the observed inflation reflects mostly the true
399 biological signal, and no further inflation correction was performed.

400

401 Next, we conducted differential methylation (DE) analysis on the confounding adjusted DNA
402 methylation data (**Methods**). We observed a global hypermethylation pattern in pre-pregnancy
403 obese samples, with 10,211 hypermethylated vs. 5,362 hypomethylated CpG sites (**Figure 3C**).
404 The top 20 differentially hypermethylated and hypomethylated CpG sites are reported in **Table**
405 **2**, respectively. These CpG sites are related to a wide variety of biological functions, including
406 inflammation (CD69, ADAM12), transcription factors (ZNF222, HMG4, LHX6, TAF3),

407 proliferation and apoptosis (HDAC4, DHRS4, LRCH3, SAFB2, CRADD, EBF3, PRKAR1B).
408 Some top DM CpG sites are directly associated with obesity, including HDAC4⁸² and PLEC1⁸³.
409
410 We further examined the distributions of these differentially methylated sites, relative to the CpG
411 island regions and promoter proximity (**Figure 3D-E**). A big fraction (42.2%) of the DM sites
412 are located in CpG islands^{84,85}, significantly higher than that from the Illumina 450K annotation
413 ($P < 2E-16$). CpG islands are more frequent in the hypermethylated sites (43.8%) than in the
414 hypomethylated sites (39.1%), which is consistent with the global hypermethylation pattern.
415 Relative to gene localization, DM sites are most frequent (39.3%) in the promoter regions
416 (including 18.7% and 20.6% in TSS200 and TSS1500 respectively) as expected.

417

418 **Functional analyses reveal the association between maternal obesity and cell cycle, immune** 419 **function and metabolic changes in the cord blood of offspring**

420 To investigate the biological functions related to the epigenome alternation, we conducted
421 systematic analysis of DM sites employing multiple methods: KEGG pathway enrichment
422 analysis, Weighted Gene Co-expression Network Analysis (WGCNA), and Protein-Protein
423 Interaction (PPI) network analysis.

424

425 KEGG pathway enrichment analysis on hypermethylated CpG sites identified five significant
426 pathways with hypergeometric $FDR < 0.05$ (**Figure 4A**), including the cell cycle, ribosome,
427 nucleocytoplasmic transport, ribosome biogenesis in eukaryotes, and mTOR signaling pathway.
428 Cell cycle, ribosome, and nucleocytoplasmic transport pathways are essential to normal cell
429 functioning. mTOR signaling pathway coordinates the nutrient-mediated metabolism, immune

430 responses and cell cycle progression, and dysregulation of mTOR could lead to various diseases
431 such as cancer and obesity⁸⁶. There was no significantly enriched pathway emerging from
432 hypomethylated CpG sites. The maternally obese group shows significantly higher methylation
433 levels in KEGG protein synthesis and immune system pathway collections compared to the
434 control group, indicating repression in immune response as well as translation and protein
435 synthesis (**Figure 4B-C**). Similarly, we further explored the differential potential, or stemness,
436 of umbilical cord Hematopoietic Stem Cells (uHSCs). We first confirmed the homogeneity of
437 uHSCs by single-cell RNA sequencing UMAP plot (**Supplemental Figure 5**). We calculated the
438 cell stemness scores using the DNA methylation beta values similar to others⁸⁷. uHSCs derived
439 from the maternally obese group exhibit significantly elevated stemness scores ($P < 0.01$) in
440 comparison to the control group (**Figure 4D**), confirming the results in KEGG pathway analysis.
441
442 Next, we applied WGCNA to cluster co-regulation of gene-level methylation, by averaging CpG
443 sites to affiliated genes (see **Methods**). Five co-expression modules are identified, using the M-
444 values adjusted for clinical confounders (**Supplemental Figure 6A**), and all modules show
445 positive correlations with maternal obesity except one. The largest turquoise module (**Figure 4E**)
446 is related to cell cycle, protein synthesis, and transport and vesicle trafficking pathways through
447 pathway enrichment analysis. Some hub genes in this module are identified, including INTU,
448 ANAPC7, and AGBL5. These genes were reported essential for maintaining cell polarity
449 (INTU)⁸⁸, proliferation (ANAPC7)⁸⁹ and glycemic control (AGBL5)⁹⁰. The brown module
450 (**Figure 4F**) is enriched with immune response pathways, in which TLR6 is identified as a hub
451 gene. The other yellow module is related to ion homeostasis, and the gray module is related to
452 the p53 pathway, apoptosis, cell senescence, and ER stress (**Supplemental Figure 6B**). The only

453 negatively correlated blue module is associated with axon guidance and VEGF signaling
454 pathway (**Supplemental Figure 6B**).

455

456 Furthermore, we examined the PPI network, using the gene-level DNA methylation as surrogates
457 (**Figure 4G**). The PPI analysis identifies 14 unique pathways (FDR < 0.05) predominantly
458 associated with hypermethylated CpG sites in the TSS200 and TSS1500 regions. The top five
459 largest pathways included ribosome, proteasome, cell cycle, axon guidance, RNA polymerase,
460 and neuroactive ligand-receptor interaction. Taken all three types of systematic analyses
461 together, cell cycle, immune function and protein synthesis are ubiquitously highlighted,
462 suggesting that these biological functions in cord blood stem cells are negatively impacted by
463 maternal obesity.

464

465 **Multi-omics analysis reveals disruptions in cell cycle and metabolic pathways**

466 To systematically investigate the epigenetic, transcriptomic, and metabolomic alterations
467 induced by maternal obesity, we performed multi-omics integration analysis on this cohort. We
468 employed DIABLO, a supervised integration method that extracts features associated with
469 maternal obesity, based on the correlations in the embedding space⁷³. **Figure 5A-C** shows that
470 methylation data provide the clearest separation between obese and control groups, confirming
471 the value of the earlier DNA methylation-centered analysis.

472

473 The top 25 features from each omic with the highest feature weights (loadings) following
474 integrated canonical correlation analysis are demonstrated in **Figure 5D-F**. The methylation
475 features with the highest weights related to maternal obesity include CpG sites involved in cell-

476 cycle control, glucose metabolism, and adipogenesis (FOXO1⁹¹), DNA repair (LIG3, SMUG1),
477 erythropoietin pathway and differentiation (EPO, CSNK2A1, CSF1), which are hypermethylated
478 in the obese group. Hypomethylation of LEP (encoding leptin) was also observed as a top
479 feature, aligning with prior findings that maternal obesity is associated with elevated maternal
480 leptin levels, a known marker of adipose tissue⁹². These featured CpG sites indicate repression
481 in fat metabolism and DNA repair and reduced differentiation potential. In the transcriptomic
482 space, many genes related to mRNA splicing (SRRM1, IGF2BP1, IGF2BP2, CNOT4) have
483 increased expression levels due to maternal obesity. Among the metabolite features, essential
484 sugars (glucose, xylose), poly-unsaturated fatty acids (oleic acids, DHA, arachidonic acid), and
485 phosphatidylcholine (PCs) are mostly decreased in the obese group; whereas most acylcarnitines
486 (C) are elevated. The metabolic changes show an overall accumulation of saturated fatty acid,
487 but repression of fat breakdown, glucose, and unsaturated fatty acid generation. As poly-
488 unsaturated fatty acids (eg. arachidonic acid) have important anti-inflammatory effects, the
489 results indicate a pro-inflammatory environment in offspring born of pre-pregnant obese
490 mothers.

491
492 **The maternal obesity classification model is predictive of KIRC, LUSC, and PAAD cancers**
493 **in TCGA**

494 Maternal pre-pregnancy obesity may predispose a higher risk of cancer and other diseases in
495 babies' later life, via epigenetic modification^{12,17}. To check this assumption, we built maternal
496 obesity random forest classification models using a total of 63 hypermethylated promoter region
497 marker CpG sites obtained from top KEGG pathways which overlapped with the 14 TCGA
498 cancer data that had sufficient numbers (n>10) of adjacent normal samples (**Supplemental**

499 **Table 2**). The maternal obesity random forest model resulted in balanced accuracy of 0.93 on the
500 obesity training data. We then applied this obesity classification model to predict the known
501 adjacent normal and tumor tissue labels from DNA methylation data of 14 TCGA cancers, each
502 of which has sufficient ($n > 10$) tumor adjacent normal samples (**Figure 6**). This allows us to
503 assess if the maternal obesity DNA methylation markers are associated with cancers. As shown
504 in **Figure 6A**, three cancer types have good prediction balanced accuracy (Bal acc) of at least 0.7:
505 LUSC (0.87), PAAD (0.83), KIRC (0.71), and two additional cancers reached 0.6: BRCA (0.60)
506 and KIRP (0.63). The other metrics, including overall accuracy and F-1 scores are shown in
507 **Figure 6B**. Thus, these results show that CpGs epigenetic markers associated with maternal
508 obesity are also potentially associated with tumorigenesis in lung, breast, pancreas and kidney.
509 Our result preliminarily supports that maternal pre-pregnancy obesity may predispose offspring
510 to increased risks in certain cancers later in life through epigenetic modifications.

511

512

513 **Discussion**

514 Maternal obesity is one of the most urgent health concerns worldwide. Pre-pregnancy maternal
515 obesity could cause various pregnancy-related complications and predispose offspring to
516 cardiometabolic complications and chronic diseases in the long term⁹. Multiple cross-continental
517 large cohort meta-analyses have shown that maternal obesity is directly associated with
518 offspring's risk of obesity, coronary heart disease, insulin resistance, and adverse
519 neurodevelopmental outcomes based on longitudinal observational studies^{9,93,94}. To directly
520 pinpoint the molecular level changes in offspring by maternal pre-pregnancy obesity, we used
521 cord blood stem cells as the studying material, which serve as a great surrogate revealing the

522 newborn's metabolism and immune system changes at the time of birth ⁹⁵. The current study
523 expands on previous effects and investigates the direct impact of maternal obesity on uHSCs
524 programming, the progenitor of the immune cell population, using a multi-omics (epigenetic,
525 gene expression, and metabolite) analysis approach from a unique multi-ethnic cohort.
526
527 Centered around methylation changes, three complimentary functional analysis approaches
528 (KEGG, WGCNA, and PPI) consistently demonstrated that maternal obesity impacts multiple
529 biological functions including hypermethylation in promoters of genes involved in cell cycle,
530 ribosome biogenesis, and mTOR signaling pathways. Moreover, mTOR signaling pathway also
531 plays a crucial role in metabolism and cell cycle regulation, disruption in this pathway leads to
532 insulin resistance and long-term diseases ⁹⁶. We observed a significant increase in stemness
533 scores among uHSCs affected by maternal obesity, aligning with expected downregulation in the
534 cell cycle gene expression due to observed hypermethylation in the promoters of these genes.
535 Higher stemness scores indicate enhanced quiescence, shifting the balance between stem cell
536 maintenance and differentiation towards the former. Unlike adult HSCs, fetal/neonatal HSCs
537 typically exhibit higher proliferation and self-renewal capabilities, crucial for blood cell
538 regeneration and innate immune system development ⁹⁷. Our findings provide strong epigenetic
539 evidence that maternal obesity compromises the maturation processes in neonatal uHSCs, which
540 may predispose newborns to immunological disorders.

541
542 The subsequent multi-omics integration analysis expanded conclusions from methylation
543 analysis to additional metabolomics readouts that are also linked to biological functions eg. cell
544 cycle and inflammatory pathway. We thus propose the conceptual model to illustrate the effect

545 of maternal pre-pregnancy obesity (**Figure 7**). Maternal obesity leads to nutrient deficiency with
546 lower levels of essential amino acids and fatty acids in the newborn blood and disrupts the lipid
547 metabolism homeostasis in offspring. These metabolite changes further induce cell membrane
548 instability and repress cell cycle progression, cell proliferation⁹⁸, enhancing the dysregulation of
549 these functions preexisting at the methylation level. Lipid dysregulation may also enhance the
550 pro-inflammatory environment, which in turn induces complications in offspring later in life,
551 such as cardiovascular diseases. Such a proposed model is also consistent with and further
552 strengthens previous studies at the metabolomics or epigenome levels. For example, previous
553 metabolomics studies of cord blood showed metabolic derangement predisposes newborns to
554 cardiometabolic and endocrine diseases, and disrupt the normal hormone function and neonatal
555 adiposity^{92,99}. Previous epigenome-wide association study (EWAS) with cord blood found a
556 strong association between DNA methylation pattern and postnatal BMI trajectory until
557 adolescent¹⁰⁰.

558 We also tested if maternal pre-pregnancy obesity can provide quantitative support to the long-
559 speculated theory of the utero origin of cancers^{10,11}. In particular, some researchers hypothesized
560 there exist higher stem cell burdens in newborn babies born from obese mothers¹². Here we
561 provide evidence that such stem cell burden is highly likely due to intergenerational DNA
562 methylation modification on some key biological functions (cell cycle, ribosome function, and
563 immune response) in the uHSCs. We built a random forest model trained on 61 maternal obesity-
564 associated CpG markers in uHSCs and applied it to predict tumor and normal tissues across 14
565 TCGA cancer types, without prior cancer-specific training. This model achieved decent balanced
566 accuracy above 0.6 for 5 out of 14 TCGA cancers investigated: LUSC, PAAD, BRCA KIRP and
567 KIRC, reflecting its cross-context predictive potential. These cancers, characterized by

568 inflammation, immune dysregulation, and epigenetic disruption, align with pathways enriched in
569 the obesity-associated markers ^{101,102}. Uncontrolled cell division, immune evasion, and chronic
570 inflammation are well-established hallmarks of cancer ¹⁰³, and these featured 61 CpG sites were
571 implicated in relevant biological pathways that were intimately connected with cancer
572 development. Aforehand results revealed a significant increase in stemness scores among uHSCs
573 affected by maternal obesity, which aligns with the observed hypermethylation and subsequent
574 downregulation of key cell cycle genes. This heightened stemness may predispose these cells to
575 malignant transformation if these epigenetic modifications persist, leading to an elevated stem
576 cell burden, disrupting normal cell cycle control, weakening immune surveillance, and ultimately
577 increasing susceptibility to cancer. While performance was lower for other cancers, likely due to
578 the small sample size limiting the detection of additional CpG biomarkers, tissue-specific
579 methylation variability and microenvironment differences ¹⁰⁴, the maternal obesity model
580 implicates its biological relevance across diverse cancers.

581 This study is the first to directly examine the granular changes in the stem cell population of cord
582 blood from babies of pre-pregnant obese mothers using a multi-omics approach. Previously, the
583 association between maternal obesity and epigenetic modifications has been investigated across
584 various tissue types (e.g., adipose tissue, liver, cord blood) and species (e.g., human, mouse) ¹⁰⁵.
585 We cross-checked our findings with these reports, many of which align providing further
586 validation of their biological significance. For example, 33 CpGs across 20 genes, such as those
587 in TAPBP (cg17621507, cg23922433, cg27385940), TNFAIP8 (cg18689486, cg07376834,
588 cg03723497,cg21130861), and AGPAT1 (cg09043226, cg25733934, cg08049198, cg18191873)
589 in our study are consistent with the cord blood leukocyte DNA methylation study from Martin et
590 al with the same study objective ¹⁰⁶. TAPBP, TNFAIP8, and AGPAT1 play roles in immune

591 function, transcriptional regulation, and lipid metabolism respectively. Additionally, our analysis
592 also identified different CpG probes within the same genes previously associated with maternal
593 obesity, offering additional insights into their epigenetic regulation. For instance, we observed
594 different CpGs in HLA-E (cg01462744, cg02942965, cg26175526), ALPK1 (cg04779144,
595 cg10855342), and PTEN (cg09472211). These genes were also reported from the Boston Birth
596 Cohort study ¹⁰⁷. We identified different hypermethylation sites on MYT1L (cg05786278,
597 cg17519749, cg21239227) and IGF1R (cg01284192, cg06596307, cg08138544, cg16918683,
598 cg26577252), genes; these genes also showed high methylation levels in the cord blood (on
599 different CpG sites) reported by Josefson et al ¹⁰⁸. Additionally, in our gene expression and
600 methylation correlation analysis of uHSC, HOXA9 and HOXA5 emerged as the top genes
601 (**Supplemental Figure 3D**), displaying strong correlations between expression and methylation
602 levels. These hypomethylated genes (HOX family genes), along with 25 additional commonly
603 identified genes, are consistent with the finding in the DNA methylation study on leukocytes of
604 cord blood samples ¹⁰⁹, linking them to maternal lipid and cholesterol levels. In our study,
605 HDAC4 and PLEC1 stand out for their strong associations with obesity-related traits among the
606 top differentially methylated CpG sites. Hypermethylation of cg05995464 in HDAC4 was
607 previously reported to be associated with childhood obesity ¹¹⁰. PLEC1 is a critical gene for
608 extracellular matrix remodeling in adipose tissue, and hypomethylation of cg20784950 in PLEC1
609 is evident in our study. Lower PLEC1 methylation was previously correlated with higher BMI
610 and obesity status ^{83,111}. Together, these comparisons underscore the robust and overlapping
611 epigenetic patterns associated with maternal pre-pregnancy obesity.

612

613 There are some caveats of this study related to the study design. First, this is a single-site study
614 with a relatively small sample size, and along with some genomic inflation the statistical power
615 of the findings is limited. This is especially the case for the gene expression omic layer, where
616 individual DE genes are lacking. This may have limited maternal obesity CpG biomarker
617 identification, which resulted in positive risk associations in some, but not all of the 14 TCGA
618 cancers, in the classification model (**Figure 6**). When the budget allows, a large-scale multi-site
619 population study is desirable. Secondly, we use the stem cell population in the cord blood as the
620 surrogate for “stemness” property investigation, to link the offspring’s disease with maternal
621 obesity. It is most feasible and practical to collect cord blood cells, and the painstaking
622 measurements of the uHSC population avoid blood cell type heterogeneity issues, which may
623 confound the cord blood DNA methylation result significantly ⁸¹. However, this approach may
624 very well be simplified and biased, as stem cells exist in many body parts of babies. Therefore,
625 extrapolations from uHSC need to be cautioned. Further, our phenotypic data collection focused
626 on the physiological and demographic information and missed socioeconomic data. Thirdly,
627 environmental, lifestyle or social determinants may act as confounders and influence the
628 observed outcomes, which are not measured nor adjustable in the study, per the protocol. Some
629 of these measurements, such as lifestyle and health insurance, can be mitigated by incorporating
630 electronic health record data, similar to what we have done ^{112,113}. Additionally, an important
631 aspect of maternal-offspring study is to longitudinally follow them up for health outcomes later
632 in life. The IRB for this study was not designed for such an investigation, unfortunately.
633 Nevertheless, this uHSC multi-omics study provides a critical initial lens peeking into the
634 immune-metabolic mechanisms, which serves as the foundation for all the possible expansion
635 work mentioned above.

636

637 **Conclusion**

638 In summary, this newborn study demonstrates the direct impact of maternal pre-pregnancy
639 obesity and on newborn blood at the multi-omics level, which includes increased cell cycle
640 arrest, impairment in the uHSCs differentiation capacity, more inflammation, and disruption in
641 lipid metabolism. We also showed maternal obesity-associated epigenetic modifications are
642 closely related to cancer markers, which could potentially help mitigate the intergenerational
643 health risks.

644

645 **Disclosure of use of AI-assisted tools including generative AI**

646 During the preparation of this work the author(s) used GPT-4.0 in order to improve the
647 readability. Prompts used in GPT-4.0 include “help me improve my writing in a more logical and
648 professional way” and “help me correct the grammar” along with a paragraph of the author's own
649 writing. After using this tool/service, the author(s) reviewed and edited the content thoroughly
650 and take(s) full responsibility for the content of the publication.

651

652 **Data availability statement**

653 DNA methylation data and bulk RNA-seq data generated in this study have been submitted and
654 will be available through the National Institutes of Health Gene Expression Omnibus (GEO)
655 with the accession number GSE273075 (GEO reviewer token: upmtkoygrlwtmb). Other datasets
656 used in this project for the analysis and validation purpose are publicly available. The placenta
657 datasets used in this article are available in the GEO repository with accession numbers
658 GSE31781, GSE36829, GSE59274, GSE44667, GSE74738, GSE49343, GSE69502, and

659 GSE98224. Cord blood metabolomics data used in this article is available in metabolomics
660 workbench with study ID ST001114. Cancer methylation datasets for BLCA, BRCA, COAD,
661 ESCA, HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, PAAD, PRAD, THCA, UCEC are available
662 in The Cancer Genome Atlas (TCGA data portal: <https://portal.gdc.cancer.gov/>).

663

664 **Availability of source code and requirements**

665 Project name: COBRE Hawaii Maternal Obesity Study

666 Project home page: https://github.com/lanagarmire/COBRE_methyl

667 Operating system(s): Windows, macOS, Linux

668 Programming language: R, Python

669 Other requirements: R \geq 4.1.0

670 License: GNU-GPL-3.0

671 Code to produce the analyses in this manuscript are available through GitHub

672 (https://github.com/lanagarmire/COBRE_methyl)

673

674 **Acknowledgments**

675 This research was supported by grants R01 LM012373 and R01 LM012907 awarded by NLM,
676 and R01 HD084633 awarded by NICHD to L.X. Garmire, as well as in part by the NCI Cancer
677 Center Support Grant (CCSG) number P30 CA071789 awarded to Genomics and Bioinformatics
678 Shared Resource (RRID:SCR_019085). This research was supported in part by training funding
679 provided by the NIH grant T32 GM141746 and Advanced Proteogenomics of Cancer (T32
680 CA140044).

681

682 **Author contributions**

683 LG envisioned this project, obtained the funding, supervised the study and revised the
684 manuscript. YD performed the data analysis, generated the figures, and wrote the initial
685 manuscript. YS collected TCGA data and built the machine learning models. RS consented
686 patients and obtained the samples from the hospital, with coordination from PB. DT and SW
687 coordinated with the patient recruitment and study. PB coordinated all the multi-omics assays.
688 PB, CL, and FA designed the DNA methylation assays. AG performed FACS sorting of cord
689 blood cells. ALJ performed the Illumina Meth 450 assay, MT supervised the Genomics Shared
690 Resource analyses and provided a critical review of the manuscript. All authors have read the
691 manuscript.

692

693

694 **Conflicts of interest**

695 None

696

697

698

699

700

701

702

703

704

705 **References**

- 706 1. Leddy, M. A., Power, M. L. & Schulkin, J. The impact of maternal obesity on maternal and
707 fetal health. *Rev. Obstet. Gynecol.* **1**, 170–178 (2008).
- 708 2. Hjalgrim, L. L. *et al.* Birth weight as a risk factor for childhood leukemia: a meta-analysis
709 of 18 epidemiologic studies. *Am. J. Epidemiol.* **158**, 724–735 (2003).
- 710 3. Harder, T., Plagemann, A. & Harder, A. Birth weight and risk of neuroblastoma: a meta-
711 analysis. *Int. J. Epidemiol.* **39**, 746–756 (2010).
- 712 4. Cnattingius, S., Lundberg, F., Sandin, S., Grönberg, H. & Iliadou, A. Birth characteristics
713 and risk of prostate cancer: the contribution of genetic factors. *Cancer Epidemiol.*
714 *Biomarkers Prev.* **18**, 2422–2426 (2009).
- 715 5. Eriksson, M. *et al.* The impact of birth weight on prostate cancer incidence and mortality in
716 a population-based study of men born in 1913 and followed up from 50 to 85 years of age.
717 *Prostate* **67**, 1247–1254 (2007).
- 718 6. Michos, A., Xue, F. & Michels, K. B. Birth weight and the risk of testicular cancer: a meta-
719 analysis. *Int. J. Cancer* **121**, 1123–1131 (2007).
- 720 7. Silva, I. dos S., De Stavola, B., McCormack, V. & Collaborative Group on Pre-Natal Risk
721 Factors and Subsequent Risk of Breast Cancer. Birth size and breast cancer risk: re-analysis
722 of individual participant data from 32 studies. *PLoS Med.* **5**, e193 (2008).
- 723 8. Van Cleave, J., Gortmaker, S. L. & Perrin, J. M. Dynamics of obesity and chronic health
724 conditions among children and youth. *JAMA* **303**, 623–630 (2010).
- 725 9. Godfrey, K. M. *et al.* Influence of maternal obesity on the long-term health of offspring.
726 *The lancet. Diabetes & endocrinology* **5**, (2017).
- 727 10. Barker, D. J. The origins of the developmental origins theory. *J. Intern. Med.* **261**, (2007).

- 728 11. Barker, D. J. In utero programming of cardiovascular disease. *Theriogenology* **53**, (2000).
- 729 12. Qiu, L. *et al.* Novel measurements of mammary stem cells in human umbilical cord blood
730 as prospective predictors of breast cancer susceptibility in later life. *Ann. Oncol.* **23**, 245–
731 250 (2012).
- 732 13. Savarese, T. M. *et al.* Correlation of umbilical cord blood hormones and growth factors with
733 stem cell potential: implications for the prenatal origin of breast cancer hypothesis. *Breast*
734 *Cancer Res.* **9**, R29 (2007).
- 735 14. Marshall, G. M. *et al.* The prenatal origins of cancer. *Nat. Rev. Cancer* **14**, 277–289 (2014).
- 736 15. Fábíán, Á., Vereb, G. & Szöllösi, J. The hitchhikers guide to cancer stem cell theory:
737 markers, pathways and therapy. *Cytometry A* **83**, 62–71 (2013).
- 738 16. Tan, B. T., Park, C. Y., Ailles, L. E. & Weissman, I. L. The cancer stem cell hypothesis: a
739 work in progress. *Lab. Invest.* **86**, 1203–1207 (2006).
- 740 17. Strohsnitter, W. C. *et al.* Correlation of umbilical cord blood haematopoietic stem and
741 progenitor cell levels with birth weight: implications for a prenatal influence on cancer risk.
742 *Br. J. Cancer* **98**, 660–663 (2008).
- 743 18. Apgar, V. A Proposal for a New Method of Evaluation of the Newborn Infant. *Anesthesia &*
744 *Analgesia* **32**, 260 (1953).
- 745 19. Aryee, M. J. *et al.* Minfi: a flexible and comprehensive Bioconductor package for the
746 analysis of Infinium DNA methylation microarrays. *Bioinformatics* **30**, 1363 (2014).
- 747 20. Morris, T. J. *et al.* ChAMP: 450k Chip Analysis Methylation Pipeline. *Bioinformatics* **30**,
748 428–430 (2014).
- 749 21. Fortin, J.-P., Triche, T. J., Jr & Hansen, K. D. Preprocessing, normalization and integration
750 of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics* **33**, 558–560

- 751 (2017).
- 752 22. Zhou, W., Laird, P. W. & Shen, H. Comprehensive characterization, annotation and
753 innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res.* **45**, e22
754 (2017).
- 755 23. Teschendorff, A. E. *et al.* A beta-mixture quantile normalization method for correcting
756 probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics* **29**,
757 189–196 (2013).
- 758 24. Chen, Y. A. *et al.* Discovery of cross-reactive probes and polymorphic CpGs in the Illumina
759 Infinium HumanMethylation450 microarray. *Epigenetics* **8**, (2013).
- 760 25. Du, P., Kibbe, W. A. & Lin, S. M. nuID: a universal naming scheme of oligonucleotides for
761 illumina, affymetrix, and other microarrays. *Biol. Direct* **2**, 16 (2007).
- 762 26. Lin, S. M., Du, P., Huber, W. & Kibbe, W. A. Model-based variance-stabilizing
763 transformation for Illumina microarray data. *Nucleic Acids Res.* **36**, e11 (2008).
- 764 27. Du, P., Kibbe, W. A. & Lin, S. M. lumi: a pipeline for processing Illumina microarray.
765 *Bioinformatics* **24**, 1547–1548 (2008).
- 766 28. Du, P. *et al.* Comparison of Beta-value and M-value methods for quantifying methylation
767 levels by microarray analysis. *BMC Bioinformatics* **11**, 587 (2010).
- 768 29. He, B. *et al.* The maternal blood lipidome is indicative of the pathogenesis of severe
769 preeclampsia. *J. Lipid Res.* **62**, (2021).
- 770 30. Chen, Y. *et al.* Maternal plasma lipids are involved in the pathogenesis of preterm birth.
771 *Gigascience* **11**, (2022).
- 772 31. van Iterson, M., van Zwet, E. W. & Heijmans, B. T. Controlling bias and inflation in
773 epigenome- and transcriptome-wide association studies using the empirical null distribution.

- 774 *Genome Biology* **18**, 1–13 (2017).
- 775 32. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for
776 removing batch effects and other unwanted variation in high-throughput experiments.
777 *Bioinformatics (Oxford, England)* **28**, (2012).
- 778 33. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and
779 microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
- 780 34. Jaffe, A. E. *et al.* Bump hunting to identify differentially methylated regions in epigenetic
781 epidemiology studies. *Int. J. Epidemiol.* **41**, 200–209 (2012).
- 782 35. Novakovic, B. *et al.* Evidence for widespread changes in promoter methylation profile in
783 human placenta in response to increasing gestational age and environmental/stochastic
784 factors. *BMC Genomics* **12**, (2011).
- 785 36. GEO Accession viewer. <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36829>.
- 786 37. Chu, T. *et al.* Comprehensive analysis of preeclampsia-associated DNA methylation in the
787 placenta. *PLoS One* **9**, (2014).
- 788 38. Blair, J. D. *et al.* Widespread DNA hypomethylation at gene enhancer regions in placentas
789 associated with early-onset pre-eclampsia. *Mol. Hum. Reprod.* **19**, (2013).
- 790 39. Hanna, C. W. *et al.* Pervasive polymorphic imprinted methylation in the human placenta.
791 *Genome Res.* **26**, (2016).
- 792 40. Blair, J. D., Langlois, S., McFadden, D. E. & Robinson, W. P. Overlapping DNA
793 methylation profile between placentas with trisomy 16 and early-onset preeclampsia.
794 *Placenta* **35**, (2014).
- 795 41. Price, E. M. *et al.* Profiling placental and fetal DNA methylation in human neural tube
796 defects. *Epigenetics Chromatin* **9**, (2016).

- 797 42. Leavey, K., Wilson, S. L., Bainbridge, S. A., Robinson, W. P. & Cox, B. J. Epigenetic
798 regulation of placental gene expression in transcriptional subtypes of preeclampsia. *Clin.*
799 *Epigenetics* **10**, (2018).
- 800 43. Wilson, S. L., Leavey, K., Cox, B. J. & Robinson, W. P. Mining DNA methylation
801 alterations towards a classification of placental pathologies. *Hum. Mol. Genet.* **27**, (2018).
- 802 44. Hansen, K. D. IlluminaHumanMethylation450kanno. ilmn12. hg19: annotation for
803 Illumina's 450k methylation arrays. *R package version 0.6. 0*.
- 804 45. Maksimovic, J., Gordon, L. & Oshlack, A. SWAN: Subset-quantile within array
805 normalization for illumina infinium HumanMethylation450 BeadChips. *Genome Biol.* **13**,
806 R44 (2012).
- 807 46. Phipson, B. & Oshlack, A. DiffVar: a new method for detecting differential variability with
808 application to methylation in cancer and aging. *Genome Biol.* **15**, 465 (2014).
- 809 47. Maksimovic, J., Gagnon-Bartsch, J. A., Speed, T. P. & Oshlack, A. Removing unwanted
810 variation in a differential methylation analysis of Illumina HumanMethylation450 array
811 data. *Nucleic Acids Res.* **43**, e106 (2015).
- 812 48. Phipson, B., Maksimovic, J. & Oshlack, A. missMethyl: an R package for analyzing data
813 from Illumina's HumanMethylation450 platform. *Bioinformatics* **32**, 286–288 (2016).
- 814 49. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids*
815 *Res.* **28**, 27–30 (2000).
- 816 50. Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. *Protein*
817 *Sci.* **28**, 1947–1951 (2019).
- 818 51. Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG
819 for taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res.* (2022)

- 820 doi:10.1093/nar/gkac963.
- 821 52. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network
822 analysis. *BMC Bioinformatics* **9**, 559 (2008).
- 823 53. Langfelder, P. & Horvath, S. Fast R Functions for Robust Correlations and Hierarchical
824 Clustering. *J. Stat. Softw.* **46**, (2012).
- 825 54. Szklarczyk, D. *et al.* The STRING database in 2021: customizable protein-protein
826 networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic*
827 *Acids Res.* **49**, D605–D612 (2021).
- 828 55. Li, H. *et al.* PAND: A Distribution to Identify Functional Linkage from Networks with
829 Preferential Attachment Property. *PLoS One* **10**, e0127968 (2015).
- 830 56. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular
831 interaction networks. *Genome Res.* **13**, 2498–2504 (2003).
- 832 57. He, B. & Garmire, L. X. ASGARD: A Single-cell Guided pipeline to Aid Repurposing of
833 Drugs. *ArXiv* (2021).
- 834 58. MacArthur, B. D. & Lemischka, I. R. Statistical mechanics of pluripotency. *Cell* **154**, 484–
835 489 (2013).
- 836 59. Martínez, O. & Reyes-Valdés, M. H. Defining diversity, specialization, and gene specificity
837 in transcriptomes through information theory. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 9709–
838 9714 (2008).
- 839 60. Kannan, S., Farid, M., Lin, B. L., Miyamoto, M. & Kwon, C. Transcriptomic entropy
840 benchmarks stem cell-derived cardiomyocyte maturation against endogenous tissue at
841 single cell level. *PLoS Comput. Biol.* **17**, e1009305 (2021).
- 842 61. Bushnell, B. BBMap: A Fast, Accurate, Splice-Aware Aligner. (2014).

- 843 62. Andrews, S. FastQC: a quality control tool for high throughput sequence data. Available
844 online. Retrieved May.
- 845 63. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21
846 (2013).
- 847 64. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for
848 assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930 (2014).
- 849 65. Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read
850 mapping by seed-and-vote. *Nucleic Acids Res.* **41**, e108 (2013).
- 851 66. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear
852 model analysis tools for RNA-seq read counts. *Genome Biology* **15**, 1–17 (2014).
- 853 67. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
854 for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 855 68. Chen, J., Xu, H., Aronow, B. J. & Jegga, A. G. Improved human disease candidate gene
856 prioritization using mouse phenotype. *BMC Bioinformatics* **8**, 392 (2007).
- 857 69. Chen, J., Aronow, B. J. & Jegga, A. G. Disease candidate gene identification and
858 prioritization using protein interaction networks. *BMC Bioinformatics* **10**, 73 (2009).
- 859 70. Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list
860 enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.* **37**, W305–11
861 (2009).
- 862 71. Schlueter, R. J. *et al.* Prepregnant Obesity of Mothers in a Multiethnic Cohort Is Associated
863 with Cord Blood Metabolomic Changes in Offspring. *J. Proteome Res.* **19**, 1361–1374
864 (2020).
- 865 72. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression

- 866 data using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2006).
- 867 73. Singh, A. *et al.* DIABLO: an integrative approach for identifying key molecular drivers
868 from multi-omics assays. *Bioinformatics* **35**, 3055 (2019).
- 869 74. Luo, W. & Brouwer, C. Pathview: an R/Bioconductor package for pathway-based data
870 integration and visualization. *Bioinformatics* **29**, 1830–1831 (2013).
- 871 75. Fang, X. *et al.* Lilikoi V2.0: a deep learning-enabled, personalized pathway-based R
872 package for diagnosis and prognosis predictions using metabolomics data. *Gigascience* **10**,
873 (2021).
- 874 76. Al-Akwaa, F. M., Yunits, B., Huang, S., Alhajaji, H. & Garmire, L. X. Lilikoi: an R
875 package for personalized pathway-based classification modeling using metabolomics data.
876 *GigaScience* **7**, (2018).
- 877 77. Heard, E. & Martienssen, R. A. Transgenerational epigenetic inheritance: myths and
878 mechanisms. *Cell* **157**, 95–109 (2014).
- 879 78. King, S. E. & Skinner, M. K. Epigenetic Transgenerational Inheritance of Obesity
880 Susceptibility. *Trends Endocrinol. Metab.* **31**, 478–494 (2020).
- 881 79. Morisako, A. K., Tauali‘i, M., Ambrose, A. J. H. & Withy, K. Beyond the Ability to Pay:
882 The Health Status of Native Hawaiians and Other Pacific Islanders in Relationship to
883 Health Insurance. *Hawaii J. Med. Public Health* **76**, 36 (2017).
- 884 80. Heslehurst, N. *et al.* The association between maternal body mass index and child obesity:
885 A systematic review and meta-analysis. *PLoS Med.* **16**, e1002817 (2019).
- 886 81. Liu, W. *et al.* Severe preeclampsia is not associated with significant DNA methylation
887 changes but cell proportion changes in the cord blood - caution on the importance of
888 confounding adjustment. *medRxiv* 2023.08.31.23294898 (2023)

- 889 doi:10.1101/2023.08.31.23294898.
- 890 82. Abu-Farha, M. *et al.* Proteomics Analysis of Human Obesity Reveals the Epigenetic Factor
891 HDAC4 as a Potential Target for Obesity. *PLoS One* **8**, (2013).
- 892 83. Rönn, T. *et al.* Impact of age, BMI and HbA1c levels on the genome-wide DNA
893 methylation and mRNA expression patterns in human adipose tissue and identification of
894 epigenetic biomarkers in blood. *Human molecular genetics* **24**, (2015).
- 895 84. Lim, W.-J., Kim, K. H., Kim, J.-Y., Jeong, S. & Kim, N. Identification of DNA-Methylated
896 CpG Islands Associated With Gene Silencing in the Adult Body Tissues of the Ogye
897 Chicken Using RNA-Seq and Reduced Representation Bisulfite Sequencing. *Front. Genet.*
898 **10**, 346 (2019).
- 899 85. Ching, T. *et al.* Genome-wide hypermethylation coupled with promoter hypomethylation in
900 the chorioamniotic membranes of early onset pre-eclampsia. *Mol. Hum. Reprod.* **20**, 885–
901 904 (2014).
- 902 86. Meng, D., Frank, A. R. & Jewell, J. L. mTOR signaling in stem and progenitor cells.
903 *Development* **145**, (2018).
- 904 87. Guo, M., Bao, E. L., Wagner, M., Whitsett, J. A. & Xu, Y. SLICE: determining cell
905 differentiation and lineage based on single cell entropy. *Nucleic Acids Res.* **45**, e54 (2017).
- 906 88. Dai, D. *et al.* Planar cell polarity effector gene *Intu* regulates cell fate-specific
907 differentiation of keratinocytes through the primary cilia. *Cell Death Differ.* **20**, 130–138
908 (2012).
- 909 89. Liu, J. & Fuchs, S. Y. Cross-talk between APC/C and CBP/p300. *Cancer Biol. Ther.* **5**,
910 (2006).
- 911 90. Corbi, S. C. T. *et al.* Expression Profile of Genes Potentially Associated with Adequate

- 912 Glycemic Control in Patients with Type 2 Diabetes Mellitus. *Journal of diabetes research*
913 **2017**, (2017).
- 914 91. Behl, T. *et al.* Exploring the Genetic Conception of Obesity via the Dual Role of FoxO. *Int.*
915 *J. Mol. Sci.* **22**, (2021).
- 916 92. Kadakia, R. *et al.* Maternal pre-pregnancy BMI downregulates neonatal cord blood LEP
917 methylation. *Pediatr. Obes.* **12 Suppl 1**, 57–64 (2017).
- 918 93. Yu, Z. *et al.* Pre-pregnancy body mass index in relation to infant birth weight and offspring
919 overweight/obesity: a systematic review and meta-analysis. *PLoS One* **8**, e61627 (2013).
- 920 94. Sureshchandra, S., Marshall, N. E. & Messaoudi, I. Impact of pregravid obesity on maternal
921 and fetal immunity: Fertile grounds for reprogramming. *J. Leukoc. Biol.* **106**, 1035–1050
922 (2019).
- 923 95. Levy, O. Innate immunity of the human newborn: distinct cytokine responses to LPS and
924 other Toll-like receptor agonists. *J. Endotoxin Res.* **11**, 113–116 (2005).
- 925 96. Ong, P. S. *et al.* Judicious Toggling of mTOR Activity to Combat Insulin Resistance and
926 Cancer: Current Evidence and Perspectives. *Front. Pharmacol.* **7**, (2016).
- 927 97. Mack, R., Zhang, L., Breslin, P. & Zhang, J. The fetal-to-adult hematopoietic stem cell
928 transition and its role in childhood hematopoietic malignancies. *Stem cell reviews and*
929 *reports* **17**, 2059 (2021).
- 930 98. Kwok, A. C. & Wong, J. T. Lipid biosynthesis and its coordination with cell cycle
931 progression. *Plant Cell Physiol.* **46**, (2005).
- 932 99. Denizli, M., Capitano, M. L. & Kua, K. L. Maternal obesity and the impact of associated
933 early-life inflammation on long-term health of offspring. *Front. Cell. Infect. Microbiol.* **12**,
934 940937 (2022).

- 935 100. Meir, A. Y. *et al.* Umbilical cord DNA methylation is associated with body mass index
936 trajectories from birth to adolescence. *EBioMedicine* **91**, 104550 (2023).
- 937 101. Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A. & Karin, M. Inflammation, Autophagy,
938 and Obesity: Common Features in the Pathogenesis of Pancreatitis and Pancreatic Cancer.
939 *Gastroenterology* **144**, 1199 (2013).
- 940 102. Sanchez, A. *et al.* Transcriptomic signatures related to the obesity paradox in patients with
941 clear cell renal cell carcinoma: a retrospective cohort study. *The Lancet. Oncology* **21**, 283
942 (2019).
- 943 103. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. *Cell* **144**, 646–
944 674 (2011).
- 945 104. Jones, P. A. & Baylin, S. B. The epigenomics of cancer. *Cell* **128**, (2007).
- 946 105. Zhao, D. *et al.* Influence of maternal obesity on the multi-omics profiles of the maternal
947 body, gestational tissue, and offspring. *Biomedicine & pharmacotherapy = Biomedecine &*
948 *pharmacotherapie* **151**, (2022).
- 949 106. Martin, C. L. *et al.* Maternal pre-pregnancy obesity, offspring cord blood DNA methylation,
950 and offspring cardiometabolic health in early childhood: an epigenome-wide association
951 study. *Epigenetics* **14**, (2019).
- 952 107. Si, J. *et al.* Maternal pre-pregnancy BMI, offspring epigenome-wide DNA methylation, and
953 childhood obesity: findings from the Boston Birth Cohort. *BMC Medicine* **21**, 1–13 (2023).
- 954 108. Josefson, J. L. *et al.* Newborn adiposity is associated with cord blood DNA methylation at
955 IGF1R and KLF7. *Obesity* **32**, 1923–1933 (2024).
- 956 109. Waldrop, S. W. *et al.* Cord blood DNA methylation of immune and lipid metabolism genes
957 is associated with maternal triglycerides and child adiposity. *Obesity* **32**, 187–199 (2024).

- 958 110. Li, Y. *et al.* Genome-wide analysis reveals that altered methylation in specific CpG loci is
959 associated with childhood obesity. *Journal of cellular biochemistry* **119**, (2018).
- 960 111. Crujeiras, A. B. *et al.* An Epigenetic Signature in Adipose Tissue Is Linked to Nicotinamide
961 N-Methyltransferase Gene Expression. *Molecular nutrition & food research* **62**, (2018).
- 962 112. Ballard, H. K., Yang, X., Mahadevan, A. D., Lemas, D. J. & Garmire, L. X. Five-Feature
963 Models to Predict Preeclampsia Onset Time From Electronic Health Record Data:
964 Development and Validation Study. *Journal of medical Internet research* **26**, (2024).
- 965 113. Zhu, H. *et al.* Discover overlooked complications after preeclampsia from three real-world
966 medical record datasets of over 100,000 pregnancies. *medRxiv* 2023.12.05.23299296 (2024)
967 doi:10.1101/2023.12.05.23299296.
- 968 114. Oesterreich, S. *et al.* High rates of loss of heterozygosity on chromosome 19p13 in human
969 breast cancer. *Br. J. Cancer* **84**, 493–498 (2001).
- 970 115. Hong, E. A., Gautrey, H. L., Elliott, D. J. & Tyson-Capper, A. J. SAFB1- and SAFB2-
971 mediated transcriptional repression: relevance to cancer. *Biochem. Soc. Trans.* **40**, 826–830
972 (2012).
- 973 116. Hammerich-Hille, S. *et al.* SAFB1 mediates repression of immune regulators and apoptotic
974 genes in breast cancer cells. *J. Biol. Chem.* **285**, 3608–3616 (2010).

975

976

977 **Figure legends**

978

979 **Figure 1. Overview of the study design and analysis.** In the preparation step, cord blood
980 plasma samples are collected for metabolome profiling and stem cell sorting. DNA and RNA
981 extraction assays are performed on the enriched stem cells for the methylation and RNA-seq
982 analyses. Downstream analyses are mainly focused on the methylation data. Bulk RNA-seq data
983 were used for validations for methylation discoveries. (Created with BioRender.com)

984

985 **Figure 2. Mother and newborns statistics of the multi-ethnic cohort from Hawaii. (A-E)**

986 Categorical variables including baby sex, maternal ethnicity, paternal ethnicity, parity and
987 gravidity between control and obese groups are shown in the barplots. P-values using Chi-square
988 test are annotated comparing control and obese groups. **(F-I)** The distributions of maternal age,
989 gestation age, maternal net weight gain during pregnancy, and maternal hemoglobin between
990 control and obese groups are compared. Mean and standard deviation are shown in boxplot. P-
991 values using t-test are annotated. **(J-M)** The distributions of baby weight, baby head
992 circumference, baby length, and APGAR score after 5 minutes of delivery between control and
993 obese groups are compared. Mean and standard deviation are shown in boxplot. P-values using t-
994 test are annotated.

995

996 **Figure 3. DNA methylation analysis on uHSCs.**

997 **(A-B)** Source of variance plot before and after confounding adjustment. F-statistics are reported
998 for each clinical factor. F statistics greater than 1 are considered to have confounding effects in
999 addition to the case/control difference due to pre-pregnancy maternal obesity. **(C)** Volcano plot

1000 of $-\log(\text{BH adjusted p-values})$ against $\log\text{FC}$. The cutoff line for adjusted p-value < 0.05 is
1001 shown as the red horizontal line. The hyper/hypo threshold is shown as a blue vertical line where
1002 $\log\text{FC}=0$. Non-significant methylation CpG sites after the differential analysis were shown in
1003 gray. Significant CpG sites are colored. **(D-E)** Normalized location distribution of differentially
1004 methylated CpG sites according to their CpG features in terms of isle regions and gene regions
1005 based on the chip annotation.

1006

1007 **Figure 4. Pathway and network analysis.** **(A)** KEGG pathway enrichment for
1008 hypermethylated CpG sites from promotor region. Enriched KEGG pathway names, adjusted p-
1009 values ($-\log_{10}$ transformed), and the size of enriched gene list are reported for CpG sites from
1010 TSS200+TSS1500 regions. The red dotted line shows the threshold cutoff for FDR at -
1011 $\log_{10}(0.05)$. **(B-C)** Violin plots of averaged beta values for KEGG protein pathway collection
1012 and immune pathway collection with Wilcoxon P-values. **(D)** Violin plots of cell entropy scores
1013 between control and obese groups with Wilcoxon P-values. **(E-F)** WGCNA network analysis
1014 results. WGCNA modules are shown for both the control and the obese group. The top two
1015 modules with largest degrees are turquoise and brown modules. Each node represents a gene.
1016 Genes co-expressed in each module are annotated. **(G)** Protein-protein interaction (PPI) network.
1017 Bipartite graphs represent enriched KEGG pathways and associated genes with significant PPIs.
1018 Red nodes represent genes with hypermethylated CpG sites. Blue nodes represent genes with
1019 hypomethylated CpG sites. Yellow nodes represented the enriched KEGG pathways. Number of
1020 inter-pathway PPIs are annotated in the rectangular boxes.

1021

1022 **Figure 5. Multi-omics integration analysis**

1023 (A-C) Omics-specific sample plots from DIABLO showing the separation of obese and control
1024 samples in methylation data, gene expression data, and metabolomics data respectively. (D-F)
1025 Importance plot of top 25 features in methylation, gene expression and metabolomics modalities
1026 with the highest loadings extracted from the embedding space. The color represents the condition
1027 which features contribute the most.

1028

1029 **Figure 6. TCGA cancer classification by the maternal obesity classification model**

1030 (A) Receiver operating characteristic (ROC) curves on the 14 TCGA cancers, using the random
1031 forest classification model built with the CpG sites of genes in the top 5 pathways associated
1032 with maternal pre-pregnancy obesity. Balanced accuracy is shown for each cancer type. (B)
1033 Barplots showing the prediction performances on these TCGA datasets, using AUC, Balanced
1034 Accuracy, and F1 score.

1035

1036 **Figure 7. A proposed conceptual model of maternal obesity's impact on neonatal**
1037 **development.**

1038

1039

1040

1041

1042

1043

1044

1045

1046 **Tables**

1047 **Table 1. Summary statistics of the study cohort.**

		Control (n=38)	Case (n=34)
Maternal Age		31.3±5.6	31.6±4.9
Gestational Week		38.9±0.5	39.0±0.3
Net Weight Gain		32.0±11.6	30.9±14.6
Hemoglobin		11.6±1.6	11.0±1.4
Maternal Ethnicity	Asian	21	8
	Caucasian	11	4
	NHPI	6	22
Paternal Ethnicity	Asian	19	11
	Caucasian	11	2
	NHPI	8	21
Baby Sex	Female	17	21
	Male	21	13
Parity	0	7	3
	1	21	7
	2	9	11
	More	1	13
Gravidity	1	6	2
	2	15	5
	3	13	8
	4	3	6
	5	1	4
	More	0	9

1048 Demographic and clinical statistics are reported for the control and maternally obese groups.

1049 **Table 2. Top 20 hypermethylated CpG sites and top 20 hypomethylated CpG sites.**

CpG	Gene	Island	Group	logFC	P.Value	adj.P.Val	Type
cg12303247	SYT11	OpenSea	3'UTR	2.188	2.44E-05	6.08E-03	Hyper
cg16818768	PSMG1	Island	TSS1500	1.605	2.15E-05	5.74E-03	Hyper
cg05995465	HDAC4	OpenSea	5'UTR	1.604	1.64E-03	4.64E-02	Hyper
cg01937701	DHRS4	Island	TSS200	1.592	1.95E-10	2.43E-05	Hyper
cg22243583	DLEU1	S_Shore	Body	1.522	2.53E-06	2.00E-03	Hyper
cg16927136	RPL35A	OpenSea	TSS1500	1.507	2.38E-10	2.43E-05	Hyper
cg08899199	ST7	S_Shore	Body	1.4	7.32E-07	1.12E-03	Hyper
cg05054115	DHRS4	Island	TSS200	1.389	6.64E-08	3.71E-04	Hyper
cg12878710	LRCH3	Island	TSS200	1.387	1.26E-06	1.47E-03	Hyper
cg05130022	HMG4	N_Shore	TSS200	1.386	1.51E-04	1.45E-02	Hyper

cg05643303	HOXC8	Island	TSS200	1.345	2.69E-05	6.34E-03	Hyper
cg07449543	CHORDC1	S_Shore	TSS200	1.342	6.31E-05	9.53E-03	Hyper
cg25016112	DENND3	OpenSea	Body	1.314	1.22E-03	4.00E-02	Hyper
cg09552166	MSL2	N_Shore	TSS200	1.296	2.29E-05	5.92E-03	Hyper
cg01003902	SAFB2	Island	TSS200	1.269	1.03E-08	1.41E-04	Hyper
cg11028445	FAM96A	N_Shore	TSS1500	1.265	1.97E-04	1.65E-02	Hyper
cg10317138	ADAM12	N_Shore	Body	1.229	5.05E-04	2.60E-02	Hyper
cg09757277	ZNF222	S_Shore	5'UTR	1.229	9.86E-08	4.24E-04	Hyper
cg04117338	CRADD	N_Shore	5'UTR	1.209	1.66E-03	4.67E-02	Hyper
cg07354583	CD69	OpenSea	Body	1.205	5.93E-07	1.01E-03	Hyper
cg04043455	EBF3	S_Shelf	Body	-2.031	6.11E-04	2.86E-02	Hypo
cg20784950	PLEC1	N_Shore	Body	-1.812	1.96E-05	5.45E-03	Hypo

cg09976051	AGA	N_Shore	Body	-1.516	1.67E-04	1.53E-02	Hypo
cg13862711	LHX6	Island	Body	-1.469	1.65E-03	4.65E-02	Hypo
cg16434331	SLC39A11	OpenSea	Body	-1.411	9.50E-08	4.24E-04	Hypo
cg05636467	EBF3	S_Shelf	Body	-1.335	1.65E-03	4.65E-02	Hypo
cg16858146	TAF3	S_Shelf	Body	-1.33	3.14E-05	6.80E-03	Hypo
cg24796644	MDGA1	Island	Body	-1.242	1.47E-05	4.79E-03	Hypo
cg11064039	PRKAR1B	Island	5'UTR	-1.227	1.58E-03	4.56E-02	Hypo
cg06833656	TBCD	OpenSea	Body	-1.219	2.67E-06	2.05E-03	Hypo
cg25430507	NXPH2	S_Shore	TSS1500	-1.152	2.08E-06	1.87E-03	Hypo
cg03485608	NXPH2	N_Shore	Body	-1.152	2.71E-06	2.05E-03	Hypo
cg00928596	MIR365-1	OpenSea	TSS200	-1.148	7.31E-05	1.03E-02	Hypo
cg12601963	NCRNA00200	Island	Body	-1.132	2.57E-06	2.02E-03	Hypo

cg22772691	SLC12A7	S_Shelf	Body	-1.123	1.79E-04	1.57E-02	Hypo
cg02584267	EBF3	OpenSea	Body	-1.121	2.38E-04	1.80E-02	Hypo
cg19282259	NCRNA00200	Island	TSS200	-1.104	3.48E-06	2.32E-03	Hypo
cg08010094	NXPH2	S_Shore	TSS1500	-1.094	1.04E-03	3.69E-02	Hypo
cg06916001	MIR365-1	OpenSea	TSS200	-1.088	5.73E-05	9.17E-03	Hypo
cg03721387	KRTAP24-1	OpenSea	3'UTR	-1.04	4.29E-06	2.53E-03	Hypo

1050 logFC, p-values, BH adjusted p-values, and CpG annotations are reported for the top 20 differentially hypermethylated CpG sites
1051 ordered by the adjusted p-values by 'limma' packages. Hypermethylated CpG sites are defined as logFC>0, whereas hypomethylated
1052 CpG sites are defined as logFC<0.

1053

1054

1055


1056

1057

Cohort Collection and Sample Preparation




medRxiv preprint doi: <https://doi.org/10.1101/2024.07.27.24310936>; this version posted December 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/)





Created with BioRender.com

1 Methylation Analyses




2 Multiomics Integration



Downstream Analyses


Enriched Stem Cells



DNA extraction

RNA extraction

Plasma



Metabolic profiling

Illumina Infinium 450K




Illumina HiSeq 4000

UPLC-MS/MS

Samples

Samples

Samples








Downstream Analyses


Integration Validation

Integration Analysis


Molecular Profiling




A. Hypermethylation KEGG Pathways




B. Immune Pathway Score (Wilcox p-val<1e-10)



C. Protein Pathway Score (Wilcox p-val<1e-10)




D. Cell Entropy (Wilcox p-val: 0.0085)




E. Module.turquoise

Correlation: 0.61 (p.value = 1e-08)








F. Module.brown



Correlation: 0.51 (p.value = 5e-06)



G. Protein-protein interaction networks





A ROC curves for obesity model prediction on TCGA**B** Obesity Model Prediction Performance Across Cancer Types

Maternal obesity

**Lipid Metabolism
(PC aa/ae, Oleic acid)**

**Nutrient Deficiency
(DHA)**

**Pro-inflammatory
Responses & Immunity**

**Membrane
damage**

**Cell cycle
repression**

Increased uHSC quiescence

**Oxidative
Stress**

**Increased
apoptosis**